Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine - Wikidata - awgldk - TriplyDB

Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine

Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine

http://www.wikidata.org/entity/Q28346742

about

Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential Durable Response of Leptomeningeal Metastasis of Breast Cancer to Salvage Intrathecal Etoposide After Methotrexate: A Case Report and Literature Review Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.Carcinomatous Meningitis from Unknown Primary Carcinoma.Intrathecal liposomal cytarabine: more friend than foe?Central nervous system disease in hematologic malignancies: historical perspective and practical applications.Contrast-Enhancing Meningeal Lesions Are Associated with Longer Survival in Breast Cancer-Related Leptomeningeal Metastasis.Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy.Treatment of neoplastic meningitis: what is the standard of care?Breast cancer brain metastases: new directions in systemic therapy Carcinomatous meningitis: Leptomeningeal metastases in solid tumors A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies.Known and emerging biomarkers of leptomeningeal metastasis and its response to treatment.Intra-CSF administration of chemotherapy medications.Optimal management of brain metastases from breast cancer. Issues and considerations.Prolonged regression of metastatic leptomeningeal breast cancer that has failed conventional therapy: a case report and review of the literature.Neoplastic Meningitis Due to Lung, Breast, and Melanoma Metastases.A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer.Safety of intrathecal administration of cytosine arabinoside and methotrexate in dogs and cats.Ventriculoperitoneal shunt for hydrocephalus caused by central nervous system metastasis.Efficacy of Liposomal Cytarabine in the Treatment of Leptomeningeal Metastasis of Breast Cancer.

P2860

Q24657256-78E61C88-2423-4065-8840-AFE3B0BC0C24 Q26799868-F7FF1E99-D2E8-4358-9DF3-4F0257D07A0C Q30366990-BA6443F1-B730-46F9-992F-1F753556DD94 Q30479900-AC6367C0-DAFE-467A-B079-D0E0AE298A84 Q33577149-157F4EB7-323B-4B69-90E9-E9A357B5B57A Q33585849-4DEC1B9B-6866-4AD5-BD58-CBB81D82D4F0 Q34096206-20ADBAE0-D150-4D18-A737-33429877308D Q35800670-39E7705A-8EBC-4809-8F98-DA3B2F325AC0 Q36107024-731A2383-8082-41E3-8A25-90A3D7D021BC Q36822500-179947EF-5B13-4D98-BF63-91C2A71B5DE4 Q36851197-5F8A0B67-3596-4987-9037-23B20FE05DCB Q37036934-59C9332D-4B2C-4D12-9CE0-E06D0D69F451 Q37690311-CB4E1EDA-6D70-4F25-B580-7F23CB57A372 Q38015719-4AC3279F-3317-4867-85FD-B87965058856 Q38067340-87055325-ADF0-4E0E-80D2-7EE025E7BEBE Q38099654-AD54FBBC-75B9-4335-BFCB-F31A8B851E22 Q39126735-418081FA-C09F-41A9-A165-4F13694EBA03 Q43651159-A8027F45-FA9F-4DCF-AEB4-9E2E36024711 Q47840420-41930BA9-A054-4D36-8B99-3640B065FDD7 Q51511668-DD234761-B6F7-46E3-BA59-27FC0EA2A36F Q55439530-3C93912F-6F9D-4188-9555-1D91E2E951A5

P2860

Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine

http://www.wikidata.org/entity/Q28346742

description

2001 nî lūn-bûn

@nan

2001 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Intrathecal treatment of neopl ...... ease formulation of cytarabine

@ast

Intrathecal treatment of neopl ...... ease formulation of cytarabine

@en

Intrathecal treatment of neopl ...... ease formulation of cytarabine

@nl

type

label

Intrathecal treatment of neopl ...... ease formulation of cytarabine

@ast

Intrathecal treatment of neopl ...... ease formulation of cytarabine

@en

Intrathecal treatment of neopl ...... ease formulation of cytarabine

@nl

prefLabel

Intrathecal treatment of neopl ...... ease formulation of cytarabine

@ast

Intrathecal treatment of neopl ...... ease formulation of cytarabine

@en

Intrathecal treatment of neopl ...... ease formulation of cytarabine

@nl

P1433

Q28346742-3B2B44E8-CCC1-4D46-BF46-9598E63598B3

P1476

Q28346742-ABA34B0C-5637-4364-9780-01C93F3ACEFB

P2093

Q28346742-0ED4FA7D-A9ED-4175-AC60-C6CF9D263C83

Q28346742-17D1D2A5-4282-4D37-B8C4-22823FA2B9D0

Q28346742-1B039448-F36A-4A3D-9E60-ECA9D0AD7686

Q28346742-20798F87-1216-4096-976E-2950822E9737

Q28346742-2A05DF69-1DE7-49AB-8250-5A6DF158ADF3

Q28346742-2E8E2DAD-9122-40E9-9700-11C8BA32CC97

Q28346742-3A66ABDA-EED3-4256-BC09-AACD05AFE10B

Q28346742-3D8D0A5B-8FAE-475A-B087-41779879DB8A

Q28346742-5692B705-CB3E-42D3-8F97-02079A324C52

Q28346742-5F550A6B-8E0B-49E0-AF4E-B1E8C4E3496C

P2860

Q28346742-1C1468F7-D999-4A50-BA65-C82692321D42

Q28346742-30F04B10-0C87-448B-90F3-D32431F2EE74

Q28346742-70AA6117-0245-4146-9DEA-C9BC37513DF8

Q28346742-89EBED90-7B23-4583-BC94-956A381AF367

Q28346742-B43201D0-1623-4259-9277-C5C42AB116D0

Q28346742-C8B7DB53-47AB-4351-A247-1335D8A07120

Q28346742-CBB6D8AE-A1E6-48DA-83AB-3D34A7C8AAE4

Q28346742-CBEC593B-C738-4596-B2B8-4A769CCBB46F

Q28346742-E3DFB116-0DC7-41C3-B2DF-A5A4F69F0CFA

Q28346742-EFB5B3A0-EDEA-4ADD-B197-F47D60AE440A

P2888

Q28346742-105F90C6-A6E2-4332-97AE-88C60B6BC2F0

P304

Q28346742-6D05C64E-A58E-4E06-B279-C0B3FE21F3BB

P31

Q28346742-C8D4F996-1CD2-4954-A9A6-DA4406102512

P356

Q28346742-2F07AA61-F36A-4D4D-9E69-8190D9C93454

P407

Q28346742-87FE58B3-5501-4675-BC70-F172F29D270C

P433

Q28346742-B4753CCA-951F-48A2-A057-E2F6737410B5

P478

Q28346742-2F147E34-FB37-41E1-9C4A-6E111126AE5A

P50

Q28346742-65B8AFBB-AAB6-4375-BEC1-74DCDA1FC353

P577

Q28346742-815C67FF-F4C9-4EC2-A22D-1F092DAFA34D

P5875

Q28346742-3F55A524-5FC1-4210-A8C3-8144DE4BB121

P6179

Q28346742-8E113B0D-A43E-406A-ABCF-79E9AAC3820C

P698

Q28346742-36751794-3872-4E80-AA7F-45CE83DD95CB

P921

Q28346742-A1AFB33E-CDA6-4C11-9C01-E6FBB3FABCA2

P932

Q28346742-24AE7BB2-9993-4C6E-B3A2-D46FF8A58E02

P356

P1433

British Journal of Cancer

P1476

Intrathecal treatment of neopl ...... ease formulation of cytarabine

@en

P2093

Aiken R

http://www.w3.org/2001/XMLSchema#string

Akerley W

http://www.w3.org/2001/XMLSchema#string

Baidas S

http://www.w3.org/2001/XMLSchema#string

Batchelor T

http://www.w3.org/2001/XMLSchema#string

Bent MJ

http://www.w3.org/2001/XMLSchema#string

Campbell T

http://www.w3.org/2001/XMLSchema#string

Chamberlain MC

http://www.w3.org/2001/XMLSchema#string

Cohn A

http://www.w3.org/2001/XMLSchema#string

Fulton D

http://www.w3.org/2001/XMLSchema#string

Gertler SZ

http://www.w3.org/2001/XMLSchema#string

P2860

Carcinomatous meningitis secondary to breast cancer: predictors of response to combined modality therapy.

Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group.

Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment.

Diagnosis and treatment of patients with meningeal carcinomatosis.

Prognostic significance of coexistent bulky metastatic central nervous system disease in patients with leptomeningeal metastases.

Extended CSF cytarabine exposure following intrathecal administration of DTC 101.

Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection.

Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections.

Intraventricular methotrexate therapy of leptomeningeal metastasis from breast carcinoma.

Leptomeningeal carcinomatosis. Presenting features and prognostic factors.

P2888

P304

157-163

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1054/BJOC.2000.1574

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

84

http://www.w3.org/2001/XMLSchema#string

P50

P577

2001-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12169153

http://www.w3.org/2001/XMLSchema#string

P6179

1033552333

http://www.w3.org/2001/XMLSchema#string

P698

11161370

http://www.w3.org/2001/XMLSchema#string

P921

P932

2363714

http://www.w3.org/2001/XMLSchema#string